Scancell's vaccine SCIB1 could help to prevent recurrence of melanoma.
Interviewed by Ellen Clarke (Commissioning Editor, Future Science Group). Richard Goodfellow is Joint-CEO of Scancell Holdings plc, a public company listed on the London Stock Exchange. He has over 25 years international experience in the pharmaceutical industry, in Big Pharma and with Biotech companies. During his time at Astra, he oversaw the launch of Losec and other key products internationally. Thereafter, he held the post of Director of Licensing and New Business Development at Scotia Pharmaceuticals, where he was involved with the company's flotation on the London Stock Exchange and successfully negotiated numerous deals. Goodfellow is also a founder of Paradigm Therapeutics, a Cambridge-based functional genomics company and is a former Director of Enact Pharma plc.
Scancell Limited, Department of Clinical Oncology, City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK.
Richard
R
Goodfellow
D000818:Animals; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D001709:Biotechnology; D019496:Cancer Vaccines / Q000276:immunology*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D004359:Drug Therapy, Combination; D006801:Humans; D016056:Immunodominant Epitopes / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D016219:Immunotherapy, Adoptive; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D012008:Recurrence; D013601:T-Lymphocytes / Q000276:immunology* / Q000637:transplantation
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016056:Immunodominant Epitopes